Leqvio Cost in Indiana 2026: Inclisiran Pricing, Coverage, and Access

What Is Inclisiran and Why Does the Price Matter?

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) therapy that blocks hepatic PCSK9 synthesis at the mRNA level, producing sustained LDL-C reductions with only two to three injections per year after the initial loading phase. The FDA approved inclisiran on December 22, 2021, making it the first siRNA agent indicated for cardiovascular risk reduction.

Because inclisiran must be administered in a clinical setting rather than self-injected at home, its cost structure differs from other PCSK9 inhibitors like evolocumab and alirocumab. The drug is billed as a medical benefit under many insurance plans rather than a pharmacy benefit, a distinction that directly affects how Indiana residents access and pay for it. PCSK9 inhibition as a drug class has demonstrated consistent LDL-C lowering across multiple randomized trials, and understanding the pricing mechanics is the first step toward affording this therapy.

For Indiana patients already on maximally tolerated statin therapy whose LDL-C remains above guideline targets, the difference between paying list price and navigating the available assistance programs can be thousands of dollars per year.

Leqvio List Price vs. Real-World Cost in Indiana

The Novartis wholesale acquisition cost for Leqvio in 2026 runs approximately $540 per month, or about $3,240 for each semi-annual injection cycle. This figure is the starting point, not what most patients actually pay.

Real-world cost depends on three variables: insurance plan type, prior-authorization status, and eligibility for manufacturer assistance. Commercially insured patients with approved prior authorization who enroll in the Novartis LEQVIO Now savings program may reduce out-of-pocket costs to $0 per dose, depending on their plan's formulary tier. The ACC/AHA cholesterol guideline identifies PCSK9 inhibition as reasonable for very-high-risk ASCVD patients who remain above an LDL-C threshold of 70 mg/dL despite maximally tolerated statins plus ezetimibe, which provides the clinical basis most insurers require before approving Leqvio.

Cash-pay patients in Indiana face the full list price at retail, which averages $540 per month across Indiana pharmacies in 2026. The only meaningful cash alternative is compounded inclisiran through a licensed 503A pharmacy, discussed in its own section below.

Indiana Medicaid Coverage for Leqvio in 2026

Indiana Medicaid does not cover Leqvio for atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) indications as of 2026. Coverage is restricted to Type 2 diabetes-related lipid management in a narrow set of circumstances, and inclisiran does not appear on Indiana's Preferred Drug List for the broader ASCVD population.

This is a significant barrier. The CDC reports that heart disease is the leading cause of death in Indiana, and a meaningful share of Medicaid beneficiaries carry ASCVD diagnoses that would otherwise qualify them for inclisiran under FDA labeling. Patients enrolled in Indiana Medicaid who believe they have a compelling clinical case may pursue a prior-authorization exception or a formulary exception request, although approval rates for non-covered biologics remain low without specific state policy changes.

The ACC's 2022 Expert Consensus Decision Pathway on novel lipid-lowering therapies explicitly recommends considering PCSK9 inhibitors for Medicaid patients with recurrent ASCVD events and LDL-C above 70 mg/dL, citing cost-effectiveness data at prevailing net prices. Clinicians treating Indiana Medicaid patients can reference this pathway in exception requests to strengthen the medical necessity argument.

Dual-eligible patients (Medicare/Medicaid) face a separate coverage analysis. Medicare Part B covers inclisiran as an administered drug when given in a physician's office, and Medicare Part D plans may list it on specialty tiers. Medicare patients should check their specific plan's formulary at medicare.gov during open enrollment.

Which Private Insurance Plans Cover Leqvio in Indiana?

Commercial coverage in Indiana has expanded since Leqvio's launch. Anthem Blue Cross Blue Shield of Indiana, UnitedHealthcare, and Cigna national plans include inclisiran on their specialty formularies, typically at Tier 4 or Tier 5, subject to prior authorization and step-therapy requirements. Formulary placement affects net cost substantially, and tier assignment changes annually during open enrollment cycles.

Step-therapy requirements are common. Most Indiana commercial plans require documented failure of, or intolerance to, at least one statin at maximum tolerated dose and often require a trial of ezetimibe before approving inclisiran. Gathering this documentation proactively shortens the prior-authorization timeline. The AHA's 2021 scientific statement on lipid management after ASCVD provides language clinicians can use when writing prior-authorization letters: the statement notes that PCSK9 inhibition is appropriate when LDL-C remains 70 mg/dL or higher despite optimized oral therapy.

Employer-sponsored self-insured plans in Indiana may have different formularies than the insurer's standard commercial plan. Patients should call the member services number on their insurance card and ask specifically whether inclisiran appears on the medical or pharmacy benefit, then request the formulary exception form if it is non-preferred or requires prior authorization.

How the Novartis LEQVIO Now Savings Program Works in Indiana

Novartis runs a co-pay assistance program called LEQVIO Now for commercially insured patients who are not covered by any federal or state government insurance program. Eligible Indiana patients can reduce their out-of-pocket cost to as low as $0 per administration, subject to annual benefit caps set by Novartis.

Enrollment requires: (1) a valid Leqvio prescription, (2) commercial insurance coverage that is not Medicare, Medicaid, CHIP, TRICARE, or any other government-funded plan, and (3) residency in the United States. Patients in Indiana can enroll through their prescribing physician's office or directly at the Novartis patient support line.

The Novartis patient assistance foundation (Novartis Patient Assistance Program) offers a separate pathway for uninsured or underinsured patients who meet income criteria, potentially providing Leqvio at no cost. Income thresholds are updated annually; patients should confirm current limits directly with Novartis.

A point that surprises many Indiana patients: the savings card does not apply to the administration fee billed separately by the injecting clinic. That facility or physician fee is billed to the patient's medical insurance independently of the drug cost itself.

Compounded Inclisiran in Indiana: What Is Legal?

503A compounding pharmacies in Indiana may legally compound inclisiran, provided the drug is prepared pursuant to a valid patient-specific prescription from a licensed Indiana prescriber. This option exists because inclisiran is not currently on FDA's list of drugs that may not be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. FDA regulations governing 503A compounding pharmacies require that each preparation meet USP standards for sterile compounding.

503B outsourcing facilities, which produce large batches without individual prescriptions, operate under stricter FDA oversight and are not the same as 503A pharmacies. For inclisiran, the relevant pathway for Indiana patients is the 503A route: a physician writes a patient-specific prescription, and the pharmacy compounds a sterile subcutaneous preparation.

The cost advantage can be substantial. While branded Leqvio runs approximately $540 per month, compounded inclisiran from licensed 503A pharmacies has been available at prices approaching $0 per month depending on the telehealth or clinical platform providing the service. Quality varies by pharmacy, so confirming that the compounding pharmacy holds current state licensure and follows USP 797 standards for sterile preparations is a reasonable step before proceeding.

Patients considering compounded inclisiran should discuss the decision with their prescribing physician. Compounded drugs are not FDA-approved and are not required to demonstrate bioequivalence to the branded product. The pharmacodynamic mechanism is the same, but manufacturing quality oversight differs from branded Leqvio. The Endocrine Society's clinical practice guidelines do not specifically address compounded PCSK9 siRNA agents, which reflects both the novelty of the class and the limited published data on compounded siRNA formulations.

Clinical Evidence Supporting Inclisiran: Why Physicians Prescribe It

Two key phase 3 trials established inclisiran's efficacy in the populations most relevant to Indiana prescribers: ORION-10 (N=1,561) enrolled patients with ASCVD, and ORION-11 (N=1,617) enrolled patients with ASCVD or ASCVD risk equivalents including HeFH. Published in the New England Journal of Medicine in 2020, these trials showed:

• ORION-10: inclisiran 284 mg subcutaneous produced a 52.3% placebo-corrected LDL-C reduction at Day 510 (P<0.001).
• ORION-11: 49.9% placebo-corrected LDL-C reduction at Day 510 (P<0.001).

Injection-site reactions occurred in 2.6% of inclisiran patients versus 0.9% placebo in the pooled analysis, and no serious adverse events were attributed to the drug at rates significantly above placebo. The ORION-4 cardiovascular outcomes trial enrolled over 15,000 patients and reported a 15% reduction in the risk of major adverse cardiovascular events compared to placebo (HR 0.85; 95% CI 0.77 to 0.94; P<0.001), providing the cardiovascular outcomes data that prior-authorization reviewers increasingly require.

The twice-yearly dosing schedule after loading is a practical advantage for Indiana patients who have difficulty adhering to daily or monthly oral regimens. Medication adherence in lipid-lowering therapy is a recognized challenge, and regimens requiring fewer touchpoints tend to show higher real-world persistence than daily pills.

Who Qualifies for Leqvio in Indiana: The FDA Indication

FDA labeling for inclisiran covers two adult populations:

1. Adults with primary hyperlipidemia (including HeFH) as an adjunct to diet and maximally tolerated statin therapy.
2. Adults with clinical ASCVD who need additional LDL-C lowering.

The label does not require a minimum LDL-C threshold, though payers routinely impose one. Most Indiana commercial insurers require LDL-C of 70 mg/dL or higher at the time of prior-authorization submission, consistent with the 2022 ACC Expert Consensus Decision Pathway. The AHA's 2019 cholesterol guideline sets 70 mg/dL as the threshold for considering PCSK9 inhibitor therapy in very-high-risk ASCVD patients, and insurers have broadly adopted this benchmark.

Homozygous familial hypercholesterolemia (HoFH) is not covered by the inclisiran label; clinicians managing HoFH patients in Indiana should consider lomitapide or evinacumab, which carry separate FDA approvals for that population.

How to Get Leqvio via Telehealth in Indiana

Telehealth prescribing of Leqvio is permitted in Indiana for established patients with documented cardiovascular diagnoses and relevant labs on file. A prescriber licensed in Indiana conducts a synchronous video or asynchronous intake visit, reviews the patient's statin history and LDL-C results, determines whether inclisiran meets clinical criteria, and writes the prescription or submits the prior-authorization request.

Indiana telehealth law requires that the prescriber-patient relationship meet the same standard of care as an in-person encounter, which means a thorough medical history, access to prior lab results, and documentation of treatment goals. Telehealth platforms that specialize in cardiovascular risk management can coordinate with Indiana-based infusion or physician offices to administer the injection, since inclisiran cannot be self-administered at home.

The telehealth visit itself typically costs between $75 and $150 for cash-pay patients, depending on the platform. CMS telehealth policy updates for 2024 have preserved the flexibility for established Medicare patients to receive evaluation and management services via telehealth for chronic conditions, which covers the type of lipid-management visit needed to initiate inclisiran.

Comparing Inclisiran to Other LDL-Lowering Options Available in Indiana

Indiana patients have several options when statin monotherapy is insufficient:

Ezetimibe is generic, costs $10 to $30 per month at most Indiana pharmacies, and lowers LDL-C by approximately 18 to 20% as an add-on to statins. A meta-analysis of 27 trials (N=49,492) confirmed its LDL-C efficacy and modest cardiovascular event reduction in IMPROVE-IT. Most payers require ezetimibe failure before approving any PCSK9 inhibitor or siRNA agent.

Evolocumab (Repatha) and alirocumab (Praluent) are monoclonal antibody PCSK9 inhibitors requiring biweekly or monthly self-injection. Both carry list prices above $500 per month, and both have established cardiovascular outcomes data from FOURIER and ODYSSEY OUTCOMES respectively. FOURIER (N=27,564) showed evolocumab reduced major cardiovascular events by 15% vs. placebo (HR 0.85; 95% CI 0.79 to 0.92; P<0.001). Self-administration at home is a practical advantage over inclisiran for patients without easy clinic access.

Bempedoic acid (Nexletol) is an oral, once-daily option for statin-intolerant patients. CLEAR Outcomes (N=13,970) showed a 13% reduction in MACE (HR 0.87; 95% CI 0.79 to 0.96; P=0.004). It costs roughly $300 to $400 per month list price and may be preferred by patients averse to injections.

For Indiana patients with LDL-C more than 40 mg/dL above their target, the magnitude of LDL-C lowering with inclisiran (around 50% reduction) typically exceeds what ezetimibe or bempedoic acid can provide alone. The ACC/AHA 2022 Expert Consensus Decision Pathway suggests a sequential approach: maximize statins, add ezetimibe, then add a PCSK9 inhibitor or inclisiran if the LDL-C target remains unmet.

Prior Authorization Steps for Indiana Prescribers

Getting inclisiran approved under a commercial Indiana plan typically requires the following documentation submitted by the prescribing physician:

1. Current LDL-C lab result (date within 3 to 6 months, per plan policy).
2. Evidence of maximally tolerated statin therapy, with dose and duration.
3. Documentation of ezetimibe use or medical contraindication to ezetimibe.
4. Confirmed ASCVD diagnosis (ICD-10 codes I25.10, I63.x, I70.x as applicable) or HeFH (ICD-10 E78.01).
5. Clinical note documenting the therapeutic goal and rationale for inclisiran over continued oral therapy.

Many Indiana payers use third-party prior-authorization processors (Magellan Rx, CVS Caremark, AcariaHealth) for specialty cardiometabolic drugs. CMS guidelines on prior authorization processes require decisions within 72 hours for urgent requests and 7 calendar days for standard requests under Medicare Advantage, a timeline Indiana commercial plans often mirror voluntarily.

Appeals succeed more often when the prescriber submits a peer-to-peer review request within the plan's window, typically 10 to 30 days after the initial denial. Attaching the ORION-4 cardiovascular outcomes data and the ACC/AHA guideline recommendation to the appeal letter provides the clinical evidence base reviewers are required to consider.

A Practical Cost Decision Framework for Indiana Patients

The right cost pathway depends on insurance status and clinical urgency:

Commercially insured, prior authorization approved: Enroll in the Novartis LEQVIO Now savings card immediately. Out-of-pocket cost may reach $0 per dose. Confirm whether inclisiran is on the medical benefit (billed by the administering clinic) or the pharmacy benefit (dispensed through specialty pharmacy) to avoid surprise billing.

Commercially insured, prior authorization denied: File an appeal with the ORION-4 outcomes data and the ACC/AHA guideline language. Simultaneously request a peer-to-peer review. If the second denial stands, ask whether a formulary exception is available.

Indiana Medicaid only: Inclisiran is not covered for ASCVD. Pursue aggressive oral therapy (statin plus ezetimibe plus bempedoic acid if tolerated), and ask your prescriber to submit a formulary exception with clinical documentation. Consider compounded inclisiran through a 503A pharmacy if the telehealth platform you use offers that pathway and your prescriber is willing to write the prescription.

Uninsured or underinsured: Apply for the Novartis Patient Assistance Program. If income criteria are not met, discuss compounded inclisiran with a licensed Indiana telehealth prescriber. Confirm the 503A pharmacy's state licensure and USP 797 compliance before dispensing.

Medicare Part B: Confirm your Medicare Advantage plan's formulary or, for traditional Medicare, verify Part B coverage. The Part B deductible and 20% coinsurance apply unless you have supplemental coverage.

Ask your prescribing physician for a written LDL-C goal in mg/dL so you can track whether the therapy is achieving target reduction, which matters both clinically and for continued prior-authorization renewals. NCBI's StatPearls on familial hypercholesterolemia provides a useful reference on LDL-C treatment targets that patients can share with their care team.